Phase 3 Clinical Trials With Primary Completion Dates in April 2026
This is a list of Phase 3 trials with primary completion dates in April 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | 2026-04-01 | Phase 3 | NCT04462770 | A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome |
| NTLA | Intellia Therapeutics, Inc. | 2026-04-01 | Phase 3 | NCT06634420 | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) |
| OCS | Oculis Holding AG | 2026-04-01 | Phase 3 | NCT06172257 | A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) |
| PTGX | Protagonist Therapeutics, Inc. | 2026-04-01 | Phase 3 | NCT06033586 | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera |
| VRDN | Viridian Therapeutics, Inc. | 2026-04-01 | Phase 3 | NCT06812325 | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) |
| VRDN | Viridian Therapeutics, Inc. | 2026-04-01 | Phase 3 | NCT06625398 | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) |
| VTGN | Vistagen Therapeutics, Inc. | 2026-04-01 | Phase 3 | NCT06615557 | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) |
| ZLDPF | Zealand Pharma A/S | 2026-04-01 | Phase 3 | NCT03905707 | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS |
| ZLDPF | Zealand Pharma A/S | 2026-04-01 | Phase 3 | NCT04881825 | Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial |